Milestone Pharmaceuticals Inc. cash flow to debt ratio of -84.01% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Milestone Pharmaceuticals Inc.'s free cash flow has decreased 70.85% from $-28.88M last year to $-49.34M, signaling decreasing performance

Milestone Pharmaceuticals Inc.'s debt to equity ratio is 3.81, which means that the company's assets are unhealthy financed, signaling financial risk.

Milestone Pharmaceuticals Inc.'s debt has decreased relative to shareholder equity from 4.17 last year to 3.81 today, signaling strengthened financials

Milestone Pharmaceuticals Inc. has a net cash position, so leverage is healthy.

Milestone Pharmaceuticals Inc.'s interest coverage ratio is -9.30, which means that the company struggles to meet interest obligations, signaling financial risk.

Milestone Pharmaceuticals Inc. has insufficient data to evaluate this check.

Milestone Pharmaceuticals Inc.'s short-term assets of $111.92M exceed its short-term liabilities of $13.98M

Milestone Pharmaceuticals Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Milestone Pharmaceuticals Inc.'s return on equity of -339.38%, is lower than 15.00%, indicating bad performance

Milestone Pharmaceuticals Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Milestone Pharmaceuticals Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Milestone Pharmaceuticals Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Milestone Pharmaceuticals Inc. has negative free cash flow, indicating cash burn

Milestone Pharmaceuticals Inc.'s yearly earnings has decreased 51.88% since last year from $-41.52M to $-63.06M, signaling decreasing performance

Milestone Pharmaceuticals Inc.'s yearly revenue has increased % since last year from $0.00 to $1.55M, signaling increasing performance

ROIC -37.64% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Milestone Pharmaceuticals Inc.'s 3-year revenue CAGR of -32.38% is negative, indicating declining revenue over the past 3 years

Milestone Pharmaceuticals Inc. had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance

Milestone Pharmaceuticals Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Milestone Pharmaceuticals Inc. has insufficient data to evaluate this check.

Milestone Pharmaceuticals Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Milestone Pharmaceuticals Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Milestone Pharmaceuticals Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Milestone Pharmaceuticals Inc. has insufficient data to evaluate this check.

Milestone Pharmaceuticals Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Milestone Pharmaceuticals Inc. has a price-to-book ratio of 4.55x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Milestone Pharmaceuticals Inc. has a price-to-sales ratio of 91.97x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue